|  |  |
| --- | --- |
| Address | House # 65, Road # 8/A (New), Dhanmondi, Dhaka-1209; Factory: Maijdee Court, Noakhali  <Tel:+88-02-8129915,9146009>;  Fax:+88-02-9146013, email:info@silvapharma.com  web: www. Silvapharma.com |
| Nature of Business | Manufacturing & Marketing of Pharmaceuticals Finished Products |
| Major Products | Tablet, Capsule, Liquid & Dry Syrup |
| Market for the products | Local Market |
| BSEC’s Consent for IPO | June 28, 2018 |
| Issue Date of Prospectus | July 02, 2018 |
| Subscription Open | July 29, 2018 |
| Subscription Close | August 05, 2018 |
| Security Trading Code | SILVAPHL |
| Public Offer of Ordinary Shares | 300mn |
| Offer Price | Tk. 10 each (at par) |
| Authorized Capital | Tk. 1,500mn |
| Pre-IPO Paid-up Capital | Tk. 1,000mn |
| IPO Size | Tk. 300mn |
| Post IPO Paid-up Capital | Tk. 1,300mn |
| Min. size for IPO subscription (per lot) | 500 |
| Foreign Currency reqd. for NRB and Foreign Applicants (per Lot) | USD 60.25 or GBP 45.85 or EUR 51.97 |
| Use of IPO proceeds | |  |  | | --- | --- | | Particulars | Amount (BDT) | | Capital Machineries | 122.50mn (40.83%) | | Factory Building Construction | 56.00mn (18.67%) | | Repayment of Term Loan | 99.00mn (33.00%) | | IPO Expenses | 22.50mn (07.50%) | | Total | 220.00mn (100%) | |
| NAV Per Share | Tk. 16.48 as on June 30, 2017 |
| Earning Per Share (EPS) | Tk. 1.03 (for the year ended June **30, 2017)** |
| Dividend History | 5% Cash in 2015-16 |
| Issue Manager | Prime Finance Capital Management Limited & Imperial Capital Ltd. |
| Auditor | Mahfel Huq & Co |